share_log

Clearmind Medicine | EFFECT: Others

Clearmind Medicine | EFFECT:其他

SEC announcement ·  03/25 06:03
Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on March 22, 2024. The notice, identified by Accession Number 0001213900-24-024410 and Submission Type POS AM, signifies that the company's filing has been formally accepted by the SEC. The effectiveness of the filing, associated with File Number 333-276913, is a critical step in the regulatory process for Clearmind Medicine Inc.
Clearmind Medicine Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on March 22, 2024. The notice, identified by Accession Number 0001213900-24-024410 and Submission Type POS AM, signifies that the company's filing has been formally accepted by the SEC. The effectiveness of the filing, associated with File Number 333-276913, is a critical step in the regulatory process for Clearmind Medicine Inc.
在美國上市的公司Clearmind Medicine Inc. 已於2024年3月22日收到美國證券交易委員會(SEC)的生效通知。該通知以加入號0001213900-24-024410和提交類型爲POS AM標識,表示該公司的申請已被美國證券交易委員會正式接受。該文件編號爲333-276913,其有效性是Clearmind Medicine Inc.監管程序中的關鍵一步。
在美國上市的公司Clearmind Medicine Inc. 已於2024年3月22日收到美國證券交易委員會(SEC)的生效通知。該通知以加入號0001213900-24-024410和提交類型爲POS AM標識,表示該公司的申請已被美國證券交易委員會正式接受。該文件編號爲333-276913,其有效性是Clearmind Medicine Inc.監管程序中的關鍵一步。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息